Apnea Sleep Apnea denials in California external review

In the California DMHC record, independent physician reviewers decided 168 published external-review cases involving apnea sleep apneaand overturned the plan’s denial in 76.2%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
168
2019–2025
Overturned
76.2%
128 denials reversed

Most-fought treatments for apnea sleep apnea

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
Glucagon-Like Peptide-1 (GLP)24
83.3%
Sleep Study17
47.1%
C-Pap Machine17
70.6%
Weight Control15
86.7%
Radiofreq Ablat7
100%
Tonsillectomy3
0%

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
127
70.1%
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
41
95.1%
Typical time to a decision
15 days
Most land between 7 and 21 days
Handled as urgent
23.8%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for Zepbound.Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Medical Necessity · 2024 · IMR MN24-41814
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Inspire device implantation (hypoglossal nerve stimulator). Continuous positive airway pressure (CPAP) has traditionally been the gold standard first-line therapy in the treatment of obstructive sleep apnea (OSA). However, failure to comply with CPAP is common because it requires a nasal or full-face mask during sleep, which many patients find intolerable. As a result, tonsillectomy with or without uvulopalatopharyngoplasty (UPPP) has been utilized as an alternative surgical option. While the procedure can be effective in properly selected patients, it can fail to reduce the AHI in a meaningful manner, and the patients who do see an improvement frequently relapse. Notably, this was the case with this patient.
Experimental/Investigational · 2023 · IMR EI23-40519

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting authorization and coverage for Continuous Positive Airway Pressure (CPAP). She has witnessed apnea, morning headaches and daytime somnolence. She was referred to the sleep clinic for evaluation for obstructive sleep apnea (OSA). The sleep study report revealed mild OSA, with an apnea–hypopnea index (AHI) of 5.9. Respiratory events consisted of episodic clusters of obstructive apneas and hypopneas. Nadir oxygenation was 87.0 percent. Time spent with an oxygenation level of less than 90 percent was 0.9 minutes. Continuous positive airway pressure (CPAP) therapy was recommended at a follow-up visit. The therapy data summary noted the enrollee had an insufficient trial on auto CPAP therapy due to less than four hours of use. A repeat CPAP trial was recommended.
Medical Necessity · 2019 · IMR MN19-31632
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Inspire device (hypoglossal nerve stimulator). Findings: The physician reviewer found that As noted in the medical literature, continuous positive airway pressure (CPAP) has demonstrated excellent efficacy in the treatment of patients with OSA, with long-term adherence rates approaching 50%. Although traditional upper airway surgical procedures target the anatomic component of obstruction, upper airway stimulation improves anatomic and neuromuscular pathology. There is adequate evidence in the peer-reviewed literature to support the safety, efficacy, and long-term outcome in the treatment of OSA with hypoglossal nerve stimulation.
Medical Necessity · 2022 · IMR MN22-37304

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving apnea sleep apnea, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for apnea sleep apnea? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9